financetom
Business
financetom
/
Business
/
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
May 21, 2024 7:32 AM

10:14 AM EDT, 05/21/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.)

XPeng ( XPEV ) shares were up nearly 13% in recent Tuesday trading after the company's Q1 non-GAAP loss narrowed year-over-year while revenue rose.

The company reported a Q1 non-GAAP net loss of 1.49 Chinese renminbi ($0.21) per diluted American depositary share, narrowing from the non-GAAP net loss of 2.57 renminbi per ADS a year earlier.

Three analysts polled by Capital IQ expected a non-GAAP net loss of 1.77 renminbi per ADS.

Revenue for the quarter ended March 31 was 6.55 billion renminbi, up from 4.03 billion renminbi a year earlier.

Four analysts polled by Capital IQ expected 6.41 billion renminbi.

The company said it expects Q2 revenue of 7.5 billion renminbi to 8.3 billion renminbi. Analysts polled by Capital IQ expect 10.65 billion renminbi.

Price: 9.35, Change: +1.07, Percent Change: +12.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MoonLake Immunotherapeutics' Skin Disease Drug Hits Key Goals in Phase 3 Trials, Lags Behind UCB Rival
MoonLake Immunotherapeutics' Skin Disease Drug Hits Key Goals in Phase 3 Trials, Lags Behind UCB Rival
Sep 29, 2025
06:44 AM EDT, 09/29/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) said Monday its experimental drug, sonelokimab, met the primary and key secondary endpoints in two Phase 3 trials for moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease. The drugmaker reported that 34.8% and 35.9% of patients treated with sonelokimab achieved the primary endpoint, which is a reduction in...
Escalade Buys Gold Tip Archery Business From Revelyst
Escalade Buys Gold Tip Archery Business From Revelyst
Sep 29, 2025
06:44 AM EDT, 09/29/2025 (MT Newswires) -- Escalade (ESCA) said Monday it acquired Gold Tip, a target archery and crossbow hunting business, from Revelyst. Gold Tip makes carbon arrows and premium bow stabilizers, which will move under Escalade ownership, it said. Financial terms weren't given in the statement. ...
Alliance Laundry, backer aim to raise $751 million in US IPO
Alliance Laundry, backer aim to raise $751 million in US IPO
Sep 29, 2025
Sept 29 (Reuters) - Alliance Laundry and its backer, BDT Capital Partners, are aiming to raise as much as $751.2 million in an initial public offering in the U.S., the commercial laundry systems maker said on Monday. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shreya Biswas ) ...
Falcon Oil & Gas Jumps To 52 Week High on Beetaloo Drilling and Stimulation Update
Falcon Oil & Gas Jumps To 52 Week High on Beetaloo Drilling and Stimulation Update
Sep 29, 2025
06:46 AM EDT, 09/29/2025 (MT Newswires) -- Falcon Oil & Gas ( FOLGF ) (FO.V, AIM: FOG) jumped 8.7% to a fresh 52-week high in late-morning U.K. trading after updating current drilling and planned stimulation in Australia's Beetaloo Sub-basin. The company said its Falcon Oil & Gas Australia unit's joint-venture partner, Tamboran (B2) Pty., continues the drilling campaign. Philip O'Quigley,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved